PTSD and major depressive disorder co-occur in roughly half of patients with either diagnosis, and the comorbid presentation is more severe than either alone. The mechanistic question has been whether comorbidity reflects synergistic biology or simple symptom additivity. A 2026 rat-model study by Jiang and colleagues tests this directly, finding that PTSD-MDD comorbid rats show …
GW043 emerges as a promising new compound in the treatment of depression showcasing rapid and significant antidepressant effects by targeting NMDA receptors (NMDARs). This mechanism offers hope for those suffering from depression and sheds light on the intricate mechanisms of synaptic plasticity and neurogenesis that underpin GW043’s therapeutic benefits. Highlights: GW043’s Mechanism of Action: GW043 …
In the complex and evolving field of neuroscience, the role of synaptic plasticity in psychiatric disorders has garnered significant attention. d-Cycloserine (DCS), a partial agonist of the N-methyl-D-aspartate receptor (NMDAR), emerges as a key player in potentially revolutionizing treatment approaches. Highlights: d-Cycloserine (DCS): Initially an antimicrobial agent, DCS is now known for its role as …
Researchers have uncovered a critical role for the metabolic enzyme acetyl-CoA synthetase short-chain family member 2 (ACSS2) in depression, identifying it as a novel target for rapid-acting and long-lasting antidepressant therapies. Findings show ACSS2 regulates both brain-derived neurotrophic factor (BDNF) levels to improve synaptic plasticity and serotonin synthesis through tryptophan hydroxylase 2 (TPH2) to mediate …